NA

Naga Ananta Lakshmi Mutyala

Active Director Director DIN 08686219
DIN 08686219 First appointment Jan 2020 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Naga Ananta Lakshmi Mutyala

Data last updated:

Naga Ananta Lakshmi Mutyala is a Director at Chemome Pharma Private Limited (since 2020). The company operates in Business Services.

DIN 08686219
Primary Designation Director
Industry Business Services
First Appointment 31 Jan 2020
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Chemome Pharma Private Limited U74999TG2020PTC138896
Director31 Jan 20202020Active

Board colleagues of Naga Ananta Lakshmi Mutyala

NameDINCompanyDesignation
Durgeswara Rao Katari08686218Chemome Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Chemome Pharma Private Limited
Premium access

Shareholding and investment profile for Naga Ananta Lakshmi Mutyala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Naga Ananta Lakshmi Mutyala

Naga Ananta Lakshmi Mutyala currently holds 1 directorship: Chemome Pharma Private Limited (Director, since 31 Jan 2020).

Naga Ananta Lakshmi Mutyala was first appointed on 31 Jan 2020 as Director at Chemome Pharma Private Limited.

The current boards of Naga Ananta Lakshmi Mutyala's companies include Durgeswara Rao Katari (Chemome Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available